ITBO20050123A1 - Formulazioni farmaceutiche gastroresistenti contenenti rifaximina - Google Patents

Formulazioni farmaceutiche gastroresistenti contenenti rifaximina

Info

Publication number
ITBO20050123A1
ITBO20050123A1 IT000123A ITBO20050123A ITBO20050123A1 IT BO20050123 A1 ITBO20050123 A1 IT BO20050123A1 IT 000123 A IT000123 A IT 000123A IT BO20050123 A ITBO20050123 A IT BO20050123A IT BO20050123 A1 ITBO20050123 A1 IT BO20050123A1
Authority
IT
Italy
Prior art keywords
rifaximina
gastroresistic
pharmaceutical formulations
formulations containing
pharmaceutical
Prior art date
Application number
IT000123A
Other languages
English (en)
Inventor
Ernesto Palazzini
Maria Rosaria Pantaleo
Giuseppe Claudio Viscomi
William Zamboni
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Priority to IT000123A priority Critical patent/ITBO20050123A1/it
Publication of ITBO20050123A1 publication Critical patent/ITBO20050123A1/it
Priority to JP2008500103A priority patent/JP4827915B2/ja
Priority to RU2007136428/15A priority patent/RU2403015C2/ru
Priority to KR1020077022318A priority patent/KR101157220B1/ko
Priority to NZ556740A priority patent/NZ556740A/en
Priority to ES06723226T priority patent/ES2398564T3/es
Priority to BRPI0608853A priority patent/BRPI0608853B8/pt
Priority to ZA200707396A priority patent/ZA200707396B/xx
Priority to PCT/EP2006/002022 priority patent/WO2006094737A2/en
Priority to RS20070365A priority patent/RS52891B/en
Priority to SI200631547T priority patent/SI1874273T1/sl
Priority to EP06723226A priority patent/EP1874273B1/en
Priority to MEP-311/08A priority patent/MEP31108A/xx
Priority to CA2595033A priority patent/CA2595033C/en
Priority to US11/814,628 priority patent/US8568782B2/en
Priority to PL06723226T priority patent/PL1874273T3/pl
Priority to MX2007010889A priority patent/MX2007010889A/es
Priority to PT67232264T priority patent/PT1874273E/pt
Priority to MDA20070267A priority patent/MD4180C1/ro
Priority to CN2006800075957A priority patent/CN101137350B/zh
Priority to MEP-2008-311A priority patent/ME00199B/me
Priority to AU2006222206A priority patent/AU2006222206B2/en
Priority to DK06723226.4T priority patent/DK1874273T3/da
Priority to UAA200708881A priority patent/UA90881C2/uk
Priority to IL184695A priority patent/IL184695A/en
Priority to TNP2007000290A priority patent/TNSN07290A1/en
Priority to HRP20070432AA priority patent/HRP20070432B1/hr
Priority to MA30246A priority patent/MA29346B1/fr
Priority to NO20075046A priority patent/NO340155B1/no
Priority to HK08106217.6A priority patent/HK1115801A1/xx
Priority to US12/695,945 priority patent/US20100330129A1/en
Priority to CY20131100263T priority patent/CY1114132T1/el
Priority to US14/044,844 priority patent/US10285944B2/en
Priority to US14/097,222 priority patent/US20140186450A1/en
Priority to US16/379,709 priority patent/US20200000726A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IT000123A 2005-03-07 2005-03-07 Formulazioni farmaceutiche gastroresistenti contenenti rifaximina ITBO20050123A1 (it)

Priority Applications (35)

Application Number Priority Date Filing Date Title
IT000123A ITBO20050123A1 (it) 2005-03-07 2005-03-07 Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
DK06723226.4T DK1874273T3 (da) 2005-03-07 2006-03-06 Gastro-resistent farmaceutiske formuleringer indeholdende rifaximin
MX2007010889A MX2007010889A (es) 2005-03-07 2006-03-06 Formulaciones farmaceuticas gastrorresistentes que contienen rifaximina.
PT67232264T PT1874273E (pt) 2005-03-07 2006-03-06 Formulações farmacêuticas gastrorresistentes contendo rifaximina
KR1020077022318A KR101157220B1 (ko) 2005-03-07 2006-03-06 리팍시민을 포함하는 위내성 약학적 제제
NZ556740A NZ556740A (en) 2005-03-07 2006-03-06 Gastroresistant pharmaceutical formulations containing rifaximin
ES06723226T ES2398564T3 (es) 2005-03-07 2006-03-06 Formulaciones farmacéuticas gastrorresistentes que contienen rifaximina
BRPI0608853A BRPI0608853B8 (pt) 2005-03-07 2006-03-06 composições farmacêuticas e processo para a fabricação de microgrânulos de rifaximina gastrorresistentes
ZA200707396A ZA200707396B (en) 2005-03-07 2006-03-06 Gastroresistant pharmaceutical formulations containing rifaximin
PCT/EP2006/002022 WO2006094737A2 (en) 2005-03-07 2006-03-06 Gastroresistant pharmaceutical formulations containing rifaximin
RS20070365A RS52891B (en) 2005-03-07 2006-03-06 GASTRORE-RESISTANT PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMINE
SI200631547T SI1874273T1 (sl) 2005-03-07 2006-03-06 Gastrorezistentne farmacevtske formulacije, ki vsebujejo rifaksimin
CN2006800075957A CN101137350B (zh) 2005-03-07 2006-03-06 包含利福昔明的胃稳定药物制剂
MEP-311/08A MEP31108A (en) 2005-03-07 2006-03-06 Gastroresistant pharmaceutical formulations containing rifaximin
CA2595033A CA2595033C (en) 2005-03-07 2006-03-06 Gastroresistant pharmaceutical formulations containing rifaximin
US11/814,628 US8568782B2 (en) 2005-03-07 2006-03-06 Gastroresistant pharmaceutical formulations containing rifaximin
PL06723226T PL1874273T3 (pl) 2005-03-07 2006-03-06 Odporne na trawienie formulacje farmaceutyczne zawierające rifaksyminę
JP2008500103A JP4827915B2 (ja) 2005-03-07 2006-03-06 リファキシミンを含む胃抵抗性薬剤組成物
MDA20070267A MD4180C1 (ro) 2005-03-07 2006-03-06 Procedeu de fabricare a compoziţiilor farmaceutice cu conţinut de rifaximină sub formă de microgranule gastrorezistente, compoziţii şi utilizarea lor în tratamentul afecţiunilor inflamatoare ale intestinelor
RU2007136428/15A RU2403015C2 (ru) 2005-03-07 2006-03-06 Гастрорезистентные фармацевтические композиции, содержащие рифаксимин
EP06723226A EP1874273B1 (en) 2005-03-07 2006-03-06 Gastroresistant pharmaceutical formulations containing rifaximin
MEP-2008-311A ME00199B (me) 2005-03-07 2006-03-06 Gastrorezistentne farmaceutske formulacije koje sadrže rifaksimin
AU2006222206A AU2006222206B2 (en) 2005-03-07 2006-03-06 Gastroresistant pharmaceutical formulations containing rifaximin
UAA200708881A UA90881C2 (uk) 2005-03-07 2006-06-03 Гастрорезистентна фармацевтична композиція, що містить рифаксимін
IL184695A IL184695A (en) 2005-03-07 2007-07-18 Pharmacological preparations containing micro-granules of resistant rifaximin in the stomach, for the treatment of inflammatory diseases, their use in the preparation of drugs for the treatment of inflammatory diseases of the intestine and the process for their preparation
TNP2007000290A TNSN07290A1 (en) 2005-03-07 2007-07-24 Gastroresistant pharmaceutical formulations containing rifaximin
HRP20070432AA HRP20070432B1 (hr) 2005-03-07 2007-09-20 Gastrorezistentne farmaceutske formulacije koje sadrže rifamicin
MA30246A MA29346B1 (fr) 2005-03-07 2007-09-26 Formulations pharmaceutiques gastrorésistantes à base de rifaximine
NO20075046A NO340155B1 (no) 2005-03-07 2007-10-08 Gastroresistente farmasøytiske formuleringer inneholdende rifaximin
HK08106217.6A HK1115801A1 (en) 2005-03-07 2008-06-04 Gastroresistant pharmaceutical formulations containing rifaximin
US12/695,945 US20100330129A1 (en) 2005-03-07 2010-01-28 Gastroresistant Pharmaceutical Formulations Containing Rifaximin
CY20131100263T CY1114132T1 (el) 2005-03-07 2013-03-29 Γαστροανθεκτικες φαρμακοτεχνικες μορφες που περιεχουν ριφαξιμινη
US14/044,844 US10285944B2 (en) 2005-03-07 2013-10-02 Gastroresistant pharmaceutical formulations containing rifaximin
US14/097,222 US20140186450A1 (en) 2005-03-07 2013-12-04 Gastroresistant pharmaceutical formulations containing rifaximin
US16/379,709 US20200000726A1 (en) 2005-03-07 2019-04-09 Gastroresistant pharmaceutical formulations containing rifaximin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000123A ITBO20050123A1 (it) 2005-03-07 2005-03-07 Formulazioni farmaceutiche gastroresistenti contenenti rifaximina

Publications (1)

Publication Number Publication Date
ITBO20050123A1 true ITBO20050123A1 (it) 2005-06-06

Family

ID=36694343

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000123A ITBO20050123A1 (it) 2005-03-07 2005-03-07 Formulazioni farmaceutiche gastroresistenti contenenti rifaximina

Country Status (30)

Country Link
US (5) US8568782B2 (it)
EP (1) EP1874273B1 (it)
JP (1) JP4827915B2 (it)
KR (1) KR101157220B1 (it)
CN (1) CN101137350B (it)
AU (1) AU2006222206B2 (it)
BR (1) BRPI0608853B8 (it)
CA (1) CA2595033C (it)
CY (1) CY1114132T1 (it)
DK (1) DK1874273T3 (it)
ES (1) ES2398564T3 (it)
HK (1) HK1115801A1 (it)
HR (1) HRP20070432B1 (it)
IL (1) IL184695A (it)
IT (1) ITBO20050123A1 (it)
MA (1) MA29346B1 (it)
MD (1) MD4180C1 (it)
ME (2) MEP31108A (it)
MX (1) MX2007010889A (it)
NO (1) NO340155B1 (it)
NZ (1) NZ556740A (it)
PL (1) PL1874273T3 (it)
PT (1) PT1874273E (it)
RS (1) RS52891B (it)
RU (1) RU2403015C2 (it)
SI (1) SI1874273T1 (it)
TN (1) TNSN07290A1 (it)
UA (1) UA90881C2 (it)
WO (1) WO2006094737A2 (it)
ZA (1) ZA200707396B (it)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10280177B2 (en) 2006-09-05 2019-05-07 Alfasigma S.P.A. Use of polyols to obtain stable polymorphous forms of rifaximin
US10428086B2 (en) 2014-05-12 2019-10-01 Alfasigma S.P.A. Solvated crystal form of rifaximin, production, compositions and uses thereof
US10703763B2 (en) 2005-03-03 2020-07-07 Alfasigma S.P.A. Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
AU2016203925B2 (en) * 2007-07-06 2016-10-20 Lupin Limited Pharmaceutical compositions of rifaximin
US8974825B2 (en) * 2007-07-06 2015-03-10 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
PT2011486E (pt) * 2007-07-06 2012-08-24 Lupin Ltd Composições farmacêuticas de rifaximina
US8383151B2 (en) * 2007-07-06 2013-02-26 Lupin Limited Pharmaceutical compositions of rifaximin
JP2011500552A (ja) * 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
UA101829C2 (uk) 2008-02-25 2013-05-13 Саликс Фармасьютикалз, Лтд. ФОРМА η РИФАКСИМІНУ І ЇЇ ЗАСТОСУВАННЯ В ТЕРАПЕВТИЧНІЙ ПРАКТИЦІ
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
EP3563850A1 (en) 2008-02-26 2019-11-06 Salix Pharmaceuticals, Ltd. Methods for treating bowel diseases
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
BR112012005627A2 (pt) 2009-09-13 2017-02-21 Salix Pharmaceuticals Ltd "uso de rifaximina para preparação de um medicamento para tratar síndrome do intestino irritável (ibs)"
CZ302789B6 (cs) 2009-11-25 2011-11-09 Zentiva, K. S. Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
IT1398550B1 (it) * 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
CA2800235C (en) * 2010-03-10 2018-10-16 Lupin Limited Rifaximin ready-to-use suspension
US20170087134A1 (en) * 2010-07-12 2017-03-30 Salix Pharmaceuticals, Ltd Formulations of rifaximin and uses thereof
EA033370B1 (ru) * 2010-07-12 2019-10-31 Salix Pharmaceuticals Ltd Составы рифаксимина и их применение
CA2810598A1 (en) * 2010-09-13 2012-03-22 Cipla Limited Pharmaceutical composition
IT1403847B1 (it) * 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
ES2617402T3 (es) * 2011-06-17 2017-06-19 Evonik Röhm Gmbh Composición de recubrimiento adecuada para formas farmacéuticas o nutracéuticas
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
ITBO20120368A1 (it) * 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014015192A1 (en) * 2012-07-18 2014-01-23 Martello Jeannette Time indicator tampon
DE102012024434A1 (de) * 2012-12-14 2014-06-18 Regalismons S.A. Verstärkung der entschäumenden Wirkung von Polysiloxanen, zugehöriger Zusammensetzungen und Lösungen
CA2908525C (en) * 2013-04-12 2021-04-06 Alfa Wassermann S.P.A. Nsaid administration and related compositions, methods and systems
CN103340856A (zh) * 2013-07-09 2013-10-09 荣港生技医药科技（北京）有限公司 一种利福昔明药物组合物及其制备方法
SG10201806846RA (en) 2014-02-13 2018-09-27 Incyte Corp Cyclopropylamines as lsd1 inhibitors
PH12020552066A1 (en) 2014-02-13 2022-05-11 Incyte Corp Cyclopropylamines as lsd1 inhibitors
US9474699B2 (en) * 2014-03-31 2016-10-25 Johnson & Johnson Consumer Inc. Compostions and methods for enhancing the topical application of a basic benefit agent
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
PH12017501817B1 (en) 2015-04-03 2023-06-16 Incyte Holdings Corp Heterocyclic compounds as lsd1 inhibitors
TWI765860B (zh) 2015-08-12 2022-06-01 美商英塞特公司 Lsd1抑制劑之鹽
US9668991B1 (en) 2015-12-09 2017-06-06 International Business Machines Corporation SCFA colonic composition
TR201816080T4 (tr) * 2016-03-24 2018-11-21 Sandoz Ag Ri̇faksi̇mi̇n alfa & delta i̇çeren farmasöti̇k bi̇leşi̇m
HUE044432T2 (hu) 2016-03-24 2019-10-28 Sandoz Ag Rifaximin alfá-t tartalmazó, hosszan eltartható kompozíció
EP4137132A1 (en) 2016-09-30 2023-02-22 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
PL3416627T3 (pl) 2017-04-26 2020-06-01 Sandoz Ag Doustna postać dawkowania zawierająca rifaksyminę w postaci beta
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
WO2020208140A1 (en) 2019-04-12 2020-10-15 Sandoz Ag Rifaximin-containing granules
US20220378758A1 (en) * 2019-09-24 2022-12-01 Bausch Health Ireland Limited Rifaximin liquid formulations
WO2021260211A1 (en) * 2020-06-26 2021-12-30 Bausch Health Ireland Limited Targeted release rifaximin compositions
MX2024010030A (es) 2022-02-17 2024-09-24 Woolsey Pharmaceuticals Inc Formulaciones orales de fasudil con resina de intercambio ionico.
MX2024009983A (es) 2022-02-17 2024-08-26 Woolsey Pharmaceuticals Inc Formulaciones orales de fasudil que enmascaran el sabor.

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE751182A (fr) 1969-05-30 1970-11-03 Takeda Chemical Industries Ltd Procede de fabrication d'antibiotiques
US4206677A (en) 1978-07-17 1980-06-10 Teledyne Industries, Inc. Pedal actuator for electronic player piano
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
US5356625A (en) * 1986-08-28 1994-10-18 Enzacor Properties Limited Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals
GEP19971086B (en) * 1991-02-22 1997-12-02 Tillotts Pharma Ag Peroral Pharmaceutically Dispensed Form for Selective Introducing of the Medicine into the Intestine
IT1245907B (it) 1991-05-17 1994-10-25 Alfa Wassermann Spa Uso dei glicosaminoglicani nel trattamento della nefropatia diabetica e della neuropatia diabetica.
IT1253711B (it) * 1991-12-17 1995-08-23 Alfa Wassermann Spa Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali
IT1264494B1 (it) * 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter
US5549911A (en) * 1994-01-14 1996-08-27 Laboratoires Des Produits Ethiques Ethypharm Galenic form of 5-nitromidazole derivatives which is effective for the treatment of parasitoses and infections of the entire gastrointestinal tract
US5592021A (en) * 1995-04-26 1997-01-07 Martin Marietta Corporation Clamp for securing a power device to a heatsink
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
ATE430477T1 (de) 1996-10-16 2009-05-15 Napo Pharmaceuticals Inc Enteral-formulierungen von proanthocyanidzusammensetzungen gegen diarrhöe
IT1290679B1 (it) 1997-02-14 1998-12-10 Alfa Wassermann Spa Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US6090411A (en) * 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
DE19848260C2 (de) * 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
US20010055613A1 (en) * 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
US20030157174A1 (en) * 2000-03-23 2003-08-21 Takayuki Tsukuda Enteric granular preparations of hardly water soluble drugs characterized by containing water-repellent component
US20040170617A1 (en) * 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
ATE482692T1 (de) * 2001-07-27 2010-10-15 Astellas Pharma Inc Zusammensetzung enthaltend feine körner mit verzögerter freisetzung für in der mundhöhle schnell zerfallende tabletten
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
MXPA05000128A (es) * 2002-07-05 2005-09-30 Temrel Inc Composicion de liberacion controlada.
US20080262024A1 (en) 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7923553B2 (en) 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
CA2574188A1 (en) 2004-07-16 2006-01-26 Cipla Limited Anti-histaminic composition
US20060210483A1 (en) 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
US20060210492A1 (en) 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for treatment and prevention of periodontal conditions
US8003118B2 (en) 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
WO2007103448A2 (en) 2006-03-09 2007-09-13 Salix Pharmaceuticals, Inc. Rifaximin anti-rectal dysfunction preparation
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
PL2529626T3 (pl) 2006-05-01 2018-04-30 Napo Pharmaceuticals, Inc. Kompozycje i sposoby leczenia lub zapobiegania nowotworowi okrężnicy
KR20090047490A (ko) 2006-08-02 2009-05-12 샐릭스 파마슈티컬스 인코포레이티드 방사선 직장ｓ상결장염의 치료를 위한 조성물 및 방법
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
US8383151B2 (en) * 2007-07-06 2013-02-26 Lupin Limited Pharmaceutical compositions of rifaximin
US8974825B2 (en) 2007-07-06 2015-03-10 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
PT2011486E (pt) 2007-07-06 2012-08-24 Lupin Ltd Composições farmacêuticas de rifaximina
JP2011500552A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
MX2010004333A (es) 2007-10-17 2010-11-30 Salix Pharmaceuticals Ltd Blancos terapeuticos novedosos en enfermedad intestinal.
EP3563850A1 (en) 2008-02-26 2019-11-06 Salix Pharmaceuticals, Ltd. Methods for treating bowel diseases
ES2509892T3 (es) 2008-05-07 2014-10-20 Salix Pharmaceuticals, Ltd. Administración de un agente para limpieza del intestino y antibiótico para el tratamiento de enfermedad intestinal
RU2011116400A (ru) 2008-09-26 2012-11-10 Аска Фармасьютикал Ко., Лтд. (Jp) Средство для предотвращения и/или лечения функционального расстройства желудочно-кишечного тракта
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US20100317681A1 (en) 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
WO2010044093A1 (en) 2008-10-16 2010-04-22 Strides Arcolab Limited Formulations containing rifaximin
WO2010093776A1 (en) 2009-02-11 2010-08-19 Cedars-Sinai Medical Center Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
IT1397617B1 (it) 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
KR20120030542A (ko) 2009-06-15 2012-03-28 샐릭스 파마슈티컬스 리미티드 리팍시민에 대한 전신 노출의 조절
BR112012005627A2 (pt) 2009-09-13 2017-02-21 Salix Pharmaceuticals Ltd "uso de rifaximina para preparação de um medicamento para tratar síndrome do intestino irritável (ibs)"
JP2013508428A (ja) 2009-10-26 2013-03-07 トーマス・ジュリアス・ボロディ 新規な腸の併用療法
JP6211768B2 (ja) 2009-10-27 2017-10-11 ルピン・リミテッド リファキシミンの固溶体
WO2011061516A2 (en) 2009-11-23 2011-05-26 Cipla Limited Topical foam composition
RU2012126084A (ru) 2009-11-23 2013-12-27 Сипла Лимитед Пенная композиция для местного применения
CN101773465B (zh) 2010-01-19 2012-11-07 南京泛太化工医药研究所 以氨基酸为稳定剂的聚合物胶束载药系统
JP5896380B2 (ja) 2010-02-18 2016-03-30 サリックス ファーマスーティカルズ，リミテッド 感染症を治療するための方法
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
CA2800235C (en) 2010-03-10 2018-10-16 Lupin Limited Rifaximin ready-to-use suspension
EA033370B1 (ru) 2010-07-12 2019-10-31 Salix Pharmaceuticals Ltd Составы рифаксимина и их применение
CA2810598A1 (en) 2010-09-13 2012-03-22 Cipla Limited Pharmaceutical composition
IT1403847B1 (it) 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012076832A1 (en) 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
EP2773205B1 (en) 2011-11-02 2024-05-22 Salix Pharmaceuticals, Inc. Rifaximin for retreating diarrhea-predominant irritable bowel syndrome
CN105579458A (zh) 2013-05-17 2016-05-11 萨利克斯药品公司 在正电子发射断层摄影术(pet)扫描中使用利福昔明的方法

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10703763B2 (en) 2005-03-03 2020-07-07 Alfasigma S.P.A. Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US10280177B2 (en) 2006-09-05 2019-05-07 Alfasigma S.P.A. Use of polyols to obtain stable polymorphous forms of rifaximin
US10428086B2 (en) 2014-05-12 2019-10-01 Alfasigma S.P.A. Solvated crystal form of rifaximin, production, compositions and uses thereof

Also Published As

Publication number Publication date
BRPI0608853B8 (pt) 2021-05-25
ZA200707396B (en) 2009-08-26
TNSN07290A1 (en) 2008-12-31
US20100330129A1 (en) 2010-12-30
RU2007136428A (ru) 2009-04-20
US8568782B2 (en) 2013-10-29
WO2006094737A3 (en) 2007-02-15
HRP20070432B1 (hr) 2015-02-13
WO2006094737A8 (en) 2007-11-15
MA29346B1 (fr) 2008-03-03
CN101137350B (zh) 2013-09-11
KR101157220B1 (ko) 2012-07-09
NO20075046L (no) 2007-12-05
US20140186450A1 (en) 2014-07-03
BRPI0608853A8 (pt) 2017-12-26
DK1874273T3 (da) 2013-01-28
BRPI0608853B1 (pt) 2020-05-19
RU2403015C2 (ru) 2010-11-10
NO340155B1 (no) 2017-03-13
MD4180B2 (en) 2012-08-31
RS52891B (en) 2014-02-28
MEP31108A (en) 2010-10-10
US10285944B2 (en) 2019-05-14
ES2398564T3 (es) 2013-03-20
IL184695A0 (en) 2007-12-03
US20200000726A1 (en) 2020-01-02
AU2006222206A1 (en) 2006-09-14
MD20070267A (en) 2008-06-30
BRPI0608853A2 (pt) 2010-02-02
CA2595033A1 (en) 2006-09-14
MX2007010889A (es) 2007-11-23
KR20070117616A (ko) 2007-12-12
PL1874273T3 (pl) 2013-04-30
PT1874273E (pt) 2013-03-11
AU2006222206B2 (en) 2010-07-08
WO2006094737A2 (en) 2006-09-14
MD4180C1 (ro) 2013-03-31
EP1874273A2 (en) 2008-01-09
CA2595033C (en) 2013-05-28
HRP20070432A2 (en) 2007-11-30
CN101137350A (zh) 2008-03-05
RS20070365A (en) 2009-01-22
CY1114132T1 (el) 2016-07-27
NZ556740A (en) 2010-07-30
HK1115801A1 (en) 2008-12-12
EP1874273B1 (en) 2013-01-02
ME00199B (me) 2011-02-10
US20090011020A1 (en) 2009-01-08
SI1874273T1 (sl) 2013-04-30
IL184695A (en) 2012-12-31
US20140112987A1 (en) 2014-04-24
UA90881C2 (uk) 2010-06-10
JP4827915B2 (ja) 2011-11-30
JP2008531743A (ja) 2008-08-14

Similar Documents

Publication Publication Date Title
ITBO20050123A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
NO20075628L (no) Farmasøytiske formuleringer
RU2398586C3 (ru) Фармацевтическая композиция
BRPI0511900A (pt) composições farmacêuticas
DK1957073T3 (da) Lægemiddel
BRPI0820381A2 (pt) Formulações farmacêuticas
DK1940467T3 (da) Lægemiddelsammensætning med langvarig frigivelse
CY2014030I1 (el) Θεραπευτικες συνθεσεις που περιλαμβανουν ingenol-3-angelate
DK1907037T4 (da) Lægemiddeldispenser
DK1962873T3 (da) Farmaceutiske sammensætninger omfattende oxalat-reducerende bakterier
ITMI20050728A1 (it) Formulazione innovativa
EP1981547A4 (en) STABLE THERAPEUTIC FORMULATIONS
DK1812025T3 (da) Stabiliserede bakteriofagformuleringer
EP1871347A4 (en) PHARMACEUTICAL COMPOSITION
DK1725218T3 (da) Farmaceutisk sammensætning omfattende pimobendan
DK1587478T3 (da) Farmaceutisk sammensætning
EP1937255A4 (en) PHARMACEUTICAL COMPOSITION
EP1862184A4 (en) PHARMACEUTICAL COMPOSITION
DE602006006692D1 (de) Konzentrierte flüssige triazolfungizidformulierungen
DK2474528T3 (da) Antineoplastiske forbindelser og farmaceutiske kompositioner deraf
ATE486633T1 (de) Feste pharmazeutische zusammensetzung mit telithromycin
ITMI20042232A1 (it) Composizione farmaceutica contenente clozapina
IS7290A (is) Lyfjasamsetningar sem innihalda risperidone
ITMI20041447A1 (it) Composizione farmaceutica comprendente gabapentina
ITMI20040943A1 (it) Composizione farmaceutica cicatrizzante